Javier Caravaca Rodriguez, PhD

Title(s)Associate Researcher, Radiology
SchoolSchool of Medicine
AddressLocation Required, #001
ORCID ORCID Icon0000-0002-7971-852X Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Granada, SpainB.S.07/2009Physics
    University of Barcelona, SpainMSc06/2010Particle Physics and Cosmology
    University Autonomous of Barcelona, SpainPhD07/2014Experimental Particle Physics
    University of California, Berkeley, USPostdoctoral08/2020Neutrino Physics
    Collapse Awards and Honors
    2016Breakthrough Prize

    Collapse Overview 
    Collapse Overview
    With my background in nuclear and particle physics, and expertise in particle detectors, I develop cutting-edge radiation detectors to improve current diagnosis and therapy techniques for a number of diseases, including cancer. My main interests are exploring novel designs for SPECT and PET systems to improve their performance and expand their range of application to other pathologies. In particular, I develop new SPECT detectors for alpha and beta theranostics, explore new avenues of exploiting Cherenkov light in TOF-PET, and spearhead Monte Carlo techniques to improve dosimetry in preclinical radiation therapy.

    Collapse Research 
    Collapse Research Activities and Funding
    A high sensitivity gamma camera using a combination of Compton reconstruction and source proximity for in-vivo imaging of Ac-225
    NIH R01EB032324Oct 1, 2022 - Sep 30, 2026
    Role: Principal Investigator
    Leveraging ultra-fast Cherenkov emission in scintillator-based TOF-PET by exploiting photon wavelength sorting
    NIH R21EB032999Aug 1, 2022 - Apr 30, 2025
    Role: Principal Investigator
    First quantitative in vivo imaging of 225Ac with a collimatorless gamma camera
    UCSF Radiology and Biomedical Imaging Seed GrantSep 1, 2021 - Aug 31, 2022
    Role: PI
    Description: The main goal is to enable in vivo imaging of Ac-225 for the first time in pre-clinical settings with mice in order to allow the study of biodistributions of new developmental targeted alpha therapy radiopharmaceuticals in live animals.

    Collapse Featured Content 
    Collapse Featured Videos